Matinas BioPharma Holdings financials
$2.53−92.97%
Close Sep 28, 2026 · split-adjustedToday's change is unusually large and no split is on record yet; it may reflect an unadjusted corporate action.
Revenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$1.2M | -$1.9M | -$1.6M | -$1.6M | -$1.8M | -$1.9M | -$8.5M | -$4.4M | -$5.8M | -$5.9M | -$5.9M | -$6.1M |
| Net income | -$1.3M | -$1.9M | -$1.9M | -$2.1M | -$5.2M | -$1.7M | -$8.4M | -$4.3M | -$5.7M | -$5.8M | -$5.3M | -$6.1M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.21 | $-0.30 | $-0.30 | $-0.40 | $-1.03 | $-0.33 | $-1.66 | $-0.85 | $-1.15 | $-1.34 | $-0.62 | $-1.39 |
| EBITDA | -$1.6M | -$1.9M | -$1.6M | -$1.6M | -$1.8M | -$1.9M | -$3.9M | -$4.3M | -$5.7M | -$5.8M | -$5.8M | -$6.0M |
| Operating cash flow | -$1.8M | -$1.6M | -$1.5M | -$1.5M | -$2.0M | -$2.0M | -$3.5M | -$3.5M | -$3.1M | -$5.8M | -$4.6M | -$4.4M |
| Free cash flow | -$1.8M | -$1.6M | -$1.5M | -$1.5M | -$2.0M | -$2.0M | -$3.5M | -$3.5M | -$3.1M | -$5.8M | -$4.6M | -$4.4M |
| Diluted shares | 6.4M | 6.4M | 6.3M | 5.4M | 5.1M | 5.1M | 5.1M | 5.0M | 5.0M | 4.3M | 8.6M | 4.3M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $761.0K | $2.4M | $4.0M | $5.4M | $6.5M | $6.9M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $6.0K | $7.0K | $7.0K | $16.0K | $16.0K | $17.0K |
| Total assets | $3.4M | $5.9M | $7.2M | $9.7M | $11.4M | $12.0M |
| Total liabilities | $1.6M | $2.9M | $2.4M | $3.2M | $3.7M | $5.8M |
| Shareholders' equity | $1.8M | $3.0M | $4.8M | $6.5M | $7.7M | $6.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology